Wolinetz, Carrie D.2017-05-122017-05-122017-05-09https://hdl.handle.net/2152.5/4097Tuesday, May 9, 2017; noon to 1 p.m.; Room D1.602. "CRISPR and Gene Editing: One Tool To Rule Them All". Carrie D. Wolinetz, Ph.D., Associate Director for Science Policy, Director of the Office of Science Policy (OSP), National Institutes of Health (NIH).Advances in gene editing, particularly the development of CRISPR-cas9, have allowed for new applications of this technology, ranging from gene drives to development of new animal models for research. This emerging biotechnology is pushing the boundaries of science, even as it provides new and evolving challenges to our policy framework and oversight mechanisms. How do we ensure responsible and feasible oversight while not constraining scientific progress that expands our knowledge base and improves human health? What are the intersection points between new gene editing applications and the current policy landscape?MPEG-4 movie00:55:02enGrand RoundsClustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Associated ProteinsCRISPR-Cas SystemsGene TargetingGenomicsRNA EditingTeaching RoundsVideo987272548